Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Descending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
13668-0682-60 13668-0682 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral April 12, 2023 In Use
13668-0682-30 13668-0682 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral April 12, 2023 In Use
13668-0682-12 13668-0682 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral April 12, 2023 In Use
13668-0594-87 13668-0594 APREPITANT APREPITANT Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oct. 21, 2020 In Use
13668-0593-86 13668-0593 APREPITANT APREPITANT 125.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
13668-0592-86 13668-0592 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
13668-0592-84 13668-0592 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
13668-0591-82 13668-0591 APREPITANT APREPITANT 40.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
13668-0591-81 13668-0591 APREPITANT APREPITANT 40.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
13668-0462-74 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0462-30 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0462-01 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0453-74 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0453-30 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0453-01 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13632-0123-01 13632-0123 Tamoxifen Citrate Soltamox 10.0 mg/5mL Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Oct. 1, 2012 Aug. 1, 2018 In Use
12634-0686-04 12634-0686 Prednisolone Prednisolone 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 27, 2003 In Use
12634-0188-91 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 26, 1974 In Use
12634-0188-85 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 26, 1974 In Use
12634-0188-84 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 26, 1974 In Use
12634-0188-82 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 26, 1974 In Use
12634-0188-81 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 26, 1974 In Use
12634-0188-80 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 26, 1974 In Use
12634-0188-79 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 26, 1974 In Use
12634-0188-71 12634-0188 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 26, 1974 In Use

Found 10,000 results in 11 milliseconds — Export these results